Tammy Kruger
Adult Health · Novi, MINPI 1184135766
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations.
Across 168 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$304
- SK Life Science, Inc.$266
- UCB, Inc.$238
- Sumitomo Pharma America, Inc.$197
- AbbVie$193
- Dexcom, Inc.$176
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,03898%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $304 |
| SK Life Science, Inc. | 13 | $266 |
| UCB, Inc. | 13 | $238 |
| Sumitomo Pharma America, Inc. | 13 | $197 |
| AbbVie | 14 | $193 |
| Dexcom, Inc. | 3 | $176 |
| Lundbeck LLC | 11 | $176 |
| Merck | 8 | $144 |
| Otsuka America Pharmaceutical, Inc. | 7 | $129 |
| Urovant Sciences Inc | 1 | $125 |
| Neurocrine Biosciences, Inc. | 5 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Lilly USA, LLC | 5 | $84 |
| Amgen | 5 | $80 |
| Exact Sciences | 5 | $75 |
| Bayer | 5 | $75 |
| AstraZeneca | 4 | $69 |
| Paratek Pharmaceuticals, Inc. | 4 | $59 |
| Novartis | 3 | $50 |
| Novo Nordisk | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 4 | $46 |
| Mannkind Corporation | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Boston Scientific | 1 | $29 |
| GSK | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $21 |
| Abbott | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Vivus LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Organogenesis Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,097 in reported general payments places this provider in the 85th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $27,825 |
| XifaxanRifaximin | 18 | $26,740 |
| JanuviaSitagliptin Phosphate | 31 | $15,569 |
| RexultiBrexpiprazole | 14 | $9,181 |
| XareltoRivaroxaban | 17 | $8,795 |
| NucyntaTapentadol Hcl | 12 | $7,895 |
| TradjentaLinagliptin | 23 | $6,032 |
| FarxigaDapagliflozin Propanediol | 13 | $4,655 |
| Potassium Chloride | 109 | $4,210 |
| JardianceEmpagliflozin | 11 | $3,361 |
| Divalproex Sodium | 50 | $2,587 |
| Gabapentin | 93 | $2,492 |
| Buspirone Hcl | 97 | $2,416 |
| Lorazepam | 262 | $1,953 |
| Lacosamide | 21 | $1,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $89 | $26,74018 claims |
| MerckJanuvia | $144 | $15,56931 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $129 | $9,18114 claims |
| AstraZenecaFarxiga | $69 | $4,65513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 527 adult health providers in Michigan.
Other adult health in Novi
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Susanne QuallichAnn Arbor$42K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Deniene KingAnn Arbor$14K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
- Mary KaiserKalamazoo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.